Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Karyopharm Therapeutics (KPTI) Operating Leases (2019 - 2025)

Historic Operating Leases for Karyopharm Therapeutics (KPTI) over the last 7 years, with Q4 2025 value amounting to $5.7 million.

  • Karyopharm Therapeutics' Operating Leases fell 1443.68% to $5.7 million in Q4 2025 from the same period last year, while for Dec 2025 it was $5.7 million, marking a year-over-year decrease of 1443.68%. This contributed to the annual value of $5.7 million for FY2025, which is 1443.68% down from last year.
  • Latest data reveals that Karyopharm Therapeutics reported Operating Leases of $5.7 million as of Q4 2025, which was down 1443.68% from $6.0 million recorded in Q3 2025.
  • Over the past 5 years, Karyopharm Therapeutics' Operating Leases peaked at $10.7 million during Q1 2021, and registered a low of $955000.0 during Q2 2024.
  • For the 5-year period, Karyopharm Therapeutics' Operating Leases averaged around $6.2 million, with its median value being $6.3 million (2025).
  • Its Operating Leases has fluctuated over the past 5 years, first tumbled by 7877.78% in 2024, then surged by 55455.5% in 2025.
  • Over the past 5 years, Karyopharm Therapeutics' Operating Leases (Quarter) stood at $9.0 million in 2021, then crashed by 32.02% to $6.1 million in 2022, then plummeted by 54.26% to $2.8 million in 2023, then soared by 140.66% to $6.7 million in 2024, then dropped by 14.44% to $5.7 million in 2025.
  • Its Operating Leases was $5.7 million in Q4 2025, compared to $6.0 million in Q3 2025 and $6.3 million in Q2 2025.